Ki20227
|
|
|
- CAS号:
- 623142-96-1
- 英文名:
- N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea
- 英文别名:
- Ki20227;CS-1094;KI20227; KI 20227;KI20227; KI-20227; KI 20227;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea;1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea;1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea;Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-
- 中文名:
- Ki20227
- 中文别名:
- KI20227,C-FMS抑制剂;1-(4-((6,7-二甲基-4-基)氧基)-2-甲氧基苯基)-3-(1-(噻唑-2-基)乙基)脲;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
- CBNumber:
- CB42484677
- 分子式:
- C24H24N4O5S
- 分子量:
- 480.54
- MOL File:
- 623142-96-1.mol
|
|
|
Ki20227化学性质
-
沸点:
-
621.8±55.0 °C(Predicted)
-
|
-
密度:
-
1.327
-
|
-
储存条件:
-
Sealed in dry,Store in freezer, under -20°C
-
|
-
溶解度:
-
≥48.1 mg/mL in DMSO; insoluble in H2O; ≥8.6 mg/mL in EtOH with gentle warming and ultrasonic
-
|
-
形态:
-
Brown powder.
-
|
-
酸度系数(pKa):
-
12.03±0.46(Predicted)
-
|
Ki20227性质、用途与生产工艺
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲是一种 c-fms 酪氨酸激酶抑制剂，可在骨转移模型中抑制破骨细胞分化和溶骨性骨破坏。
Ki20227 是一种口服活性的 c-Fms tyrosine kinase(CSF1R) 的高选择性抑制剂，对 c-Fms、vascular endothelial growth factor receptor-2 (KDR/VEGFR-2)、stem cell factor receptor (c-Kit) 和 platelet-derived growth factor receptor beta (PDGFRβ) 的IC50值为2 nM、12 nM、451 nM和217 nM。
| Target | Value |
c-Fms
(Cell-free assay)
|
2 nM
|
VEGFR2
(Cell-free assay)
|
12 nM
|
PDGFRβ
(Cell-free assay)
|
217 nM
|
c-Kit
(Cell-free assay)
|
451 nM
|
Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively.
Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
Cell Viability Assay
|
Cell Line:
|
M-NFS-60 cells, HUVEC cells, human A375 melanoma cells
|
|
Concentration:
|
0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM
|
|
Incubation Time:
|
72 hours
|
|
Result:
|
100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively.
|
Cell Viability Assay
|
Cell Line:
|
RAW264.7 cell lysate
|
|
Concentration:
|
0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM
|
|
Incubation Time:
|
1 hour
|
|
Result:
|
Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
|
Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas.
ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice.
|
Animal Model:
|
4-week-old male F344/NJcl-rnu rats
|
|
Dosage:
|
10, 20, and 50 mg/kg
|
|
Administration:
|
Orally; once per day for 20 days
|
|
Result:
|
Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas.
|
Ki20227
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-10408 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
Ki20227 | 623142-96-1 | 2mg | 820元 |
| 2024/01/25 | HY-10408 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
Ki20227 | 623142-96-1 | 5mg | 1400元 |
623142-96-1, Ki20227 相关搜索:
- 合成有机化合物配体
- 蛋白酪氨酸激酶
- KI20227,C-FMS抑制剂
- 1-(4-((6,7-二甲基-4-基)氧基)-2-甲氧基苯基)-3-(1-(噻唑-2-基)乙基)脲
- N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
- 623142-96-1
- Ki20227
- KI20227; KI 20227
- CS-1094
- KI20227; KI-20227; KI 20227
- 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea
- 1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea
- Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-
- N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea